Peptides›Longevity›Chitomur

Chitomur

/ Khavinson-tradition urinary bladder muscle bioregulator (KE-class)

SPECULATIVEN = 0 · TESTING PENDING

ALIAS · Chitomur · Urinary muscle bioregulator

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Khavinson-tradition urinary bladder muscle bioregulator (KE-class)CATEGORY · Longevity

Tier 4. The Russian-origin literature includes a single small Russian-language randomized blind clinical study in elderly women with hyperactive bladder (Gomberg 2013, Adv Gerontol). Sample size and methodology fall short of the standard expected for FDA review, and there is no independent Western replication.

§ B · Mechanism of action

Chitomur is presented within the Khavinson peptide-bioregulator framework as a short peptide preparation targeting urinary bladder smooth muscle. The class-level mechanistic hypothesis is sequence-specific DNA binding and transcriptional modulation in tissue-resident cells. Chitomur-specific molecular characterisation is absent from indexed primary literature; the available evidence concerns clinical-level urodynamic endpoints rather than the molecular mechanism.

§ C · Human clinical evidence

Tier 4. The Gomberg 2013 Russian-language clinical report describes a randomized blind trial of chitomur in elderly women with hyperactive bladder, with reduction in urgency and incontinence episodes and improvement in quality-of-life self-assessment. The sample, blinding details, and pharmacovigilance structure fall short of FDA-grade trial standards, and the work has not been independently replicated in Western literature.

§ D · Primary literature

PubMed28976156Gomberg VG et al. — Correction of age related bladder function decrease with peptide geroprotector in women · Advances in Gerontology · human-phase-2Russian-language randomized blind trial of chitomur in elderly women with hyperactive bladder reported reductions in imperative urge episodes and urge incontinence, with improvement in patient self-assessed quality of life and no observed adverse events.Limitations: Russian-language journal; modest sample size; blinding and analytic detail below FDA-grade trial standards; not independently replicated.2013

§ F · Safety signal

The Gomberg 2013 report describes no observed side effects in the studied population. No comprehensive Western post-marketing or pharmacovigilance database exists.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication. The single small clinical study is published in Russian and has not been reproduced or extended by independent labs. Vendor-sold material in the US research-chemical channel is sold against claims of bladder regeneration that the published record cannot support, and buyers cannot cross-check vendor product identity against any pharmaceutical reference standard.